← About this guide

FREE PREVIEW

Weight-Loss Peptides

Read trial results, harms, formulation differences and treatment withdrawal in context.

2 sectionsEvidence: 2026-10-27 selected-source checks

AI-assisted editorial edition · Independent clinical review pending.

Before you read

Medical notice: This selected-source evidence-reading edition is educational material for a conversation with a qualified clinician. It does not diagnose a condition, recommend a medicine, supplement, injection or dose, or replace individualized care. Do not start, combine, stop or restart a treatment using this guide. Human editorial and independent clinical review are pending. Purchases and PDF downloads are not yet available.

What this edition can and cannot answer

Selected-source evidence-reading edition covering semaglutide STEP 1, tirzepatide SURMOUNT-1 and SURMOUNT-5, withdrawal evidence, dated pharmaceutical labeling and online product-quality findings. No complete comparative clinical synthesis, treatment selection, dosing or stack instructions.

  • Selected-source editorial edition: five cited scholarly reports were reconciled in full; SURMOUNT-5 remains abstract/registry-limited. A registry or protocol is not a completed journal appraisal. Independent approvals remain pending.
  • STEP 1 and SURMOUNT-1 are different placebo-controlled trials. Their averages do not supply a randomized comparison between medicines. [1] [2]
  • Withdrawal studies have different designs and baselines; study averages do not predict one person’s outcome. [3] [4]
  • Human editorial, independent clinical, legal, accessibility and reader-test approvals are pending. Purchases and PDF downloads are not yet available.

SECTION 01

Weight-Loss Peptides: Results, Tradeoffs and Stopping

Compare the claim with the tested product, population, outcome and follow-up. Use the findings table, then bring the worksheet and your questions to the clinician responsible for your care.

STEP 1 studied subcutaneous semaglutide against placebo; SURMOUNT-1 studied tirzepatide against placebo, and SURMOUNT-5 directly compared the two medicines under its own trial conditions. [1] [2] [5]

Selected-source checks: 27 October 2026. Five cited scholarly reports were reconciled in full; SURMOUNT-5 remains abstract/registry-limited. Independent review and broader clinical synthesis remain pending.

SECTION 02

What the selected studies found

Read each row within its own population, comparison and follow-up.

Study and comparisonFinding in the studied populationDecisive limit
STEP 1: semaglutide vs placeboAt 68 weeks, mean body-weight change was -14.9% vs -2.4%; both groups received lifestyle intervention. [1]Adults with overweight or obesity without diabetes; this was not a tirzepatide comparison.
SURMOUNT-1: tirzepatide vs placeboAt 72 weeks, mean weight reduction across three tirzepatide groups was 15.0%-20.9% vs 3.1% with placebo. [2]Different trial from STEP 1; no comparison between medicines follows from these rows.
SURMOUNT-5: direct comparisonAt 72 weeks, mean weight change was -20.2% with tirzepatide vs -13.7% with semaglutide under the trial regimens. [5]Open-label, manufacturer-funded trial in adults with obesity without diabetes; average weight is one outcome.
STEP 1 extension: after withdrawalThe prior semaglutide group regained 11.6 percentage points during the following year; net change from original baseline was -5.6%. [3]Subset follow-up; structured lifestyle intervention also stopped.
SURMOUNT-4: continue vs withdrawOver 52 weeks after randomization, mean change was +14.0% after switch to placebo vs -5.5% with continued tirzepatide. [4]Percentages use weight at randomization after initial treatment; people who stopped before randomization are not represented.

Safety: labels contraindicate use with personal/family medullary thyroid carcinoma, MEN2 or specified hypersensitivity. They direct stopping and urgent help for persistent severe abdominal pain or serious allergic symptoms. This is not the complete safety list. [6] [7]

FOLLOW THE EVIDENCE

Sources and reading limits

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Full report checked; independent review pending

    Main report Table 2/PDF p8/printed p996 and Results/PDF pp5-6; Methods/PDF pp2-4; Table 3/PDF p10; protocol/SAP selected objective and estimand sections.

  2. Tirzepatide Once Weekly for the Treatment of Obesity

    Full report checked; independent review pending

    Main report Table 2/PDF p7/printed p211; participant flow/PDF p4; Table 4/PDF pp10-11; protocol/SAP objective/estimand sections.

  3. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

    Full report checked; independent review pending

    Main report Results 3.1-3.2/PDF pp6-7/printed pp1558-1559; Methods 2.2-2.4; protocol Amendment6/PDF pp149-155.

  4. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

    Full report checked; independent review pending

    Main report Methods/Statistical Analysis; Results/Table 2 (treatment-regimen estimand); Figure 1 and Table 3; registry NCT04660643 identifies distinct efficacy-estimand results; protocol/SAP selected sections.

  5. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

    Abstract/registry-limited finding; full journal appraisal pending; original paper linked below

    PubMed abstract and NCT05822830 registry: primary weight-change results and participant flow; selected protocol/SAP sections. Full journal report remains unavailable.

  6. WEGOVY U.S. Prescribing Information, revised June 2026

    Current official snapshot checked 27 October; human clinical/legal approval pending

    Prescribing Information §§4-8,§12 and Medication Guide; current snapshot 27 October 2026; revisedJune 2026(Wegovy) orAugust 2026(Zepbound).

  7. ZEPBOUND U.S. Prescribing Information, revised August 2026

    Current official snapshot checked 27 October; human clinical/legal approval pending

    Prescribing Information §§4-8,§12 and Medication Guide; current snapshot 27 October 2026; revisedJune 2026(Wegovy) orAugust 2026(Zepbound).

  8. Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases

    Full report checked; independent review pending

    Accepted full XML: Methods; Results and Online Vendor Characteristics table; Discussion; current PubMed PMID 39093567 metadata.

  9. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    U.S. safety context; not efficacy evidence

    Current FDA unapproved-GLP1 safety context, content 1 October 2026; checked 27 October 2026.

Edition and corrections

Web reading edition: 4 November 2026. Manuscript prepared: 2026-10-27. This web-format update does not represent a new literature search or completed clinical review.

Edition: weight-management-2026-10-27-source-checked-draft-1

Scientific interpretation, source-access limits and independent review are separate from publication of this reading view.

Report a correction →

Explore all consumer guides